| Status | Study |
| Not yet recruiting |
Study Name: Pembrolizumab and Lenvatinib in Treating Metastatic or Recurrent Differentiated Thyroid Cancer That Cannot Be Removed by Surgery Condition: Columnar Cell Variant Thyroid Gland Papillary Carcinoma Follicular Variant Thyroid Gland Pap Date: 2016-11-23 Interventions: Other: Laboratory Biomarker Analysis |
| Not yet recruiting |
Study Name: Anaplastic Thyroid Cancer and Follicular Thyroid Cancer-derived Exosomal Analysis Via Treatment of Lovastatin and Vildagliptin and Pilot Prognostic Study Via Urine Exosomal Biological Markers in Thyroid Cancer Patients Condition: Thyroid Cancer Date: 2016-07-27 |
| Recruiting |
Study Name: Iodine I-131 With or Without Selumetinib in Treating Patients With Recurrent or Metastatic Thyroid Cancer Condition: Poorly Differentiated Thyroid Gland Carcinoma Recurrent Thyroid Gland Carcinoma Date: 2015-03-16 Interventions: Radiation: Iodine I-131 Given |
| Recruiting |
Study Name: Trametinib in Increasing Tumoral Iodine Incorporation in Patients With Recurrent or Metastatic Thyroid Cancer Condition: BRAF Gene Mutation Poorly Differentiated Thyroid Gland Carcinoma Date: 2014-05-29 Interventions: Procedure: Computed Tomography |
| Suspended |
Study Name: Pre-Operative Nodal Staging of Thyroid Cancer Using Ultra-Small Superparamagnetic Iron Oxide Magnetic Resonance Imaging (USPIO MRI): Preliminary Study Condition: Papillary Carcinoma of Thyroid Metastatic to Regional Lymph Node Metastatic Medullary Thyroi Date: 2013-08-20 Interventions: Drug: Ferumoxytol Ferumoxytol |
| Suspended |
Study Name: Cabozantinib-S-Malate in Treating Patients With Refractory Thyroid Cancer Condition: Poorly Differentiated Thyroid Gland Carcinoma Recurrent Thyroid Gland Carcinoma Date: 2013-03-12 Interventions: Drug: Cabozantinib S-malate Gi |
| Active, not recruiting |
Study Name: Dabrafenib With or Without Trametinib in Treating Patients With Recurrent Thyroid Cancer Condition: Follicular Thyroid Cancer Insular Thyroid Cancer Date: 2012-10-22 Interventions: Drug: dabrafenib 150 mg orally |
| Completed |
Study Name: Metabolic Effects of Synthetic Thyroid Hormone for Thyroid Cancer Treatment Condition: Malignant Struma Ovarii Papillary Thyroid Cancer Hurthle C Date: 2011-09-24 |
| Completed |
Study Name: Iodine I 131 and Pazopanib Hydrochloride in Treating Patients With Recurrent and/or Metastatic Thyroid Cancer Previously Treated With Iodine I 131 That Cannot Be Removed By Surgery Condition: Recurrent Thyroid Cancer Stage IVA Follicular Thyroid Cancer Date: 2011-07-20 Interventions: Drug: pazopanib hydrochloride |
| Active, not recruiting |
Study Name: Cediranib Maleate With or Without Lenalidomide in Treating Patients With Thyroid Cancer Condition: Recurrent Thyroid Gland Carcinoma Stage I Thyroid Gland Follicular Car Date: 2010-09-22 Interventions: Drug: Cediranib Maleate Given |